You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 1200 Leveraging the immunocompetent Vk*MYChCRBN model of multiple myeloma to determine and overcome T cell engager antibody resistance mechanisms

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Immuno-Conjugates and Chimeric Molecules
1200 Leveraging the immunocompetent Vk*MYChCRBN model of multiple myeloma to determine and overcome T cell engager antibody resistance mechanisms

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Meermeier EW, Stein C, Sharik M, et al
1200 Leveraging the immunocompetent Vk*MYChCRBN model of multiple myeloma to determine and overcome T cell engager antibody resistance mechanisms
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.1200